JP2009526066A5 - - Google Patents

Download PDF

Info

Publication number
JP2009526066A5
JP2009526066A5 JP2008554340A JP2008554340A JP2009526066A5 JP 2009526066 A5 JP2009526066 A5 JP 2009526066A5 JP 2008554340 A JP2008554340 A JP 2008554340A JP 2008554340 A JP2008554340 A JP 2008554340A JP 2009526066 A5 JP2009526066 A5 JP 2009526066A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
drug
patient
agent
rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008554340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/003382 external-priority patent/WO2007095056A2/en
Publication of JP2009526066A publication Critical patent/JP2009526066A/ja
Publication of JP2009526066A5 publication Critical patent/JP2009526066A5/ja
Pending legal-status Critical Current

Links

JP2008554340A 2006-02-09 2007-02-08 遅速性脳室内送達 Pending JP2009526066A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77145106P 2006-02-09 2006-02-09
PCT/US2007/003382 WO2007095056A2 (en) 2006-02-09 2007-02-08 Slow intraventricular delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013171131A Division JP6129685B2 (ja) 2006-02-09 2013-08-21 遅速性脳室内送達

Publications (2)

Publication Number Publication Date
JP2009526066A JP2009526066A (ja) 2009-07-16
JP2009526066A5 true JP2009526066A5 (https=) 2010-04-08

Family

ID=38372004

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008554340A Pending JP2009526066A (ja) 2006-02-09 2007-02-08 遅速性脳室内送達
JP2013171131A Active JP6129685B2 (ja) 2006-02-09 2013-08-21 遅速性脳室内送達
JP2015188744A Active JP6408970B2 (ja) 2006-02-09 2015-09-25 遅速性脳室内送達
JP2017152871A Active JP6617125B2 (ja) 2006-02-09 2017-08-08 遅速性脳室内送達

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013171131A Active JP6129685B2 (ja) 2006-02-09 2013-08-21 遅速性脳室内送達
JP2015188744A Active JP6408970B2 (ja) 2006-02-09 2015-09-25 遅速性脳室内送達
JP2017152871A Active JP6617125B2 (ja) 2006-02-09 2017-08-08 遅速性脳室内送達

Country Status (19)

Country Link
US (3) US20090123451A1 (https=)
EP (2) EP1988823B1 (https=)
JP (4) JP2009526066A (https=)
CN (1) CN101404927A (https=)
AR (1) AR059372A1 (https=)
BR (1) BRPI0707900A2 (https=)
CA (2) CA3168881C (https=)
CY (1) CY1121822T1 (https=)
DK (1) DK1988823T3 (https=)
ES (2) ES3054134T3 (https=)
HU (1) HUE040490T2 (https=)
IL (2) IL193242A (https=)
LT (1) LT1988823T (https=)
MX (4) MX358492B (https=)
PL (1) PL1988823T3 (https=)
PT (1) PT1988823T (https=)
RU (1) RU2452368C2 (https=)
SI (1) SI1988823T1 (https=)
WO (1) WO2007095056A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
HUE040490T2 (hu) 2006-02-09 2019-03-28 Genzyme Corp Lassú intraventrikuláris szállítás
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
ES2635726T3 (es) 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico
EP2167071B1 (en) * 2007-06-13 2020-03-18 Wayne State University Board Of Governors A baclofen solution for low-volume therapeutic delivery
JP5903045B2 (ja) 2009-07-31 2016-04-13 パックスバックス, インコーポレイテッド アデノウイルスに基づくベクター
SI3998078T1 (sl) 2009-08-28 2026-02-27 Genzyme Corporation Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze
PT3103469T (pt) 2010-06-25 2021-03-04 Shire Human Genetic Therapies Administração de agentes terapêuticos no snc
KR20150020250A (ko) 2012-06-19 2015-02-25 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 당뇨병을 치료하기 위한 조성물 및 방법
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR102883778B1 (ko) 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
CA2189067A1 (en) 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
AU5551996A (en) 1995-04-17 1996-11-07 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997025446A1 (en) 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
MX340738B (es) 1996-09-13 2016-07-22 Shire Human Genetic Therapies Terapia para deficiencia de a-galactosidasa a.
US7033598B2 (en) * 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6702945B2 (en) 2000-12-28 2004-03-09 Exxonmobil Research And Engineering Company Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions
US6689756B2 (en) * 2001-03-02 2004-02-10 Integra Lifesciences Corporation Treatment of neurological disease
US20030163181A1 (en) * 2001-12-07 2003-08-28 Neuron Therapeutics, Inc. Protection of neurological tissue by direct CNS perfusion cooling
EP1575562B1 (en) * 2002-11-26 2016-10-05 Seacoast Neurosciene, Inc. Buoyant polymer particles delivering therapeutic agents
RU2253486C2 (ru) * 2003-03-03 2005-06-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ химиотерапии опухолей центральной нервной системы
US20050102708A1 (en) * 2003-03-12 2005-05-12 Laurent Lecanu Animal model simulating neurologic disease
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1638605B1 (en) * 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1730183A2 (en) 2004-01-27 2006-12-13 Compugen USA, Inc. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005095955A1 (en) * 2004-03-31 2005-10-13 Children, Youth And Women's Health Service Screening for lysosomal storage disease status
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
AR059088A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
HUE040490T2 (hu) * 2006-02-09 2019-03-28 Genzyme Corp Lassú intraventrikuláris szállítás
ES2635726T3 (es) 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico

Similar Documents

Publication Publication Date Title
JP2009526066A5 (https=)
US20220370348A1 (en) Slow intraventricular delivery
RU2018129747A (ru) Внутрижелудочковая доставка ферментов при лизосомных болезнях накопления
Huttunen et al. Intraputamenal cerebral dopamine neurotrophic factor in Parkinson's disease: a randomized, double‐blind, multicenter phase 1 trial
Ponikau et al. An exploratory trial of Cyclamen europaeum extract for acute rhinosinusitis
Prusik et al. Use of low dose ziconotide as first‐line intrathecal monotherapy
Muenzer et al. Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II
US20220401360A1 (en) Milrinone Composition and Method for Administering Same
Harb et al. Aerosol drug‐delivery and short‐term clinical outcomes of suboptimal peak inspiratory flow rate in chronic obstructive pulmonary disease
Gopal et al. Recent advances in critical care: Part II
Benakatti et al. Anaphylactic Shock in Children
Singhal et al. Practice pattern of aerosol drug therapy in ARDS patients: A secondary analysis of the Aero-in-ICU study
Asare Cost savings from using patients’ own drugs in a paediatric hospital
Xinghuan et al. Advances in Research on Delivery Systems of Anti-fibrotic Drugs
Laird et al. Acute respiratory distress syndrome—a case study
Wilson Pharmacy's all-out war on general practice
Tylki-Szymanska et al. Fabrazyme® therapy in pediatric patients with Fabry disease: Improvements in quality-of-life measures
Hussar New drugs 2015, part 3
Paul Total Spinal after Shoulder Surgery.
Vongkasem et al. Successful Treatment of Allopurinol Desensitization in Gouty Arthritis Patient with Allopurinol and Colchicine Drug Allergies: A Case Report
Jenkins Asthma management-Part 1: assessing severity and optimising lung function
HK1248161B (en) Milrinone composition and method for administering same
Hunt Salmeterol/fluticasone propionate single inhaler administration potentially cost saving
WO2006080415A1 (ja) 膀胱障害を治療または予防するための組成物および方法
CN1981773A (zh) 治疗免疫相关性疾病的药物制剂